| 臺大學術典藏 |
2022-02-16T03:16:56Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:55Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; Liu T.-H.; YU-YUN SHAO; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-16T03:16:55Z |
Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan
|
Wu T.-C.; Hsu C.-H.; Sun W.-Z.; Chen H.-M.; Lin C.-P.; YU-YUN SHAO |
| 臺大學術典藏 |
2022-02-14T23:55:05Z |
Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan
|
Wu, Tsung Che; CHIH-HUNG HSU; WEI-ZEN SUN; Chen, Ho Min; CHIH-PENG LIN; YU-YUN SHAO |
| 臺大學術典藏 |
2021-12-14T23:12:34Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen, Ching Tso; Liu, Tsung Hao; YU-YUN SHAO; KAO-LANG LIU; PO-CHIN LIANG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2021-09-14T23:18:28Z |
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
|
YU-YUN SHAO; Sun, Nai Yun; YUNG-MING JENG; YAO-MING WU; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey Chi; ANN-LII CHENG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2021-08-15T00:08:05Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
BANG-BIN CHEN; YU-YUN SHAO; Lin, Zhong Zhe; CHIH-HUNG HSU; ANN-LII CHENG; CHIUN HSU; PO-CHIN LIANG; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2021-08-03T07:10:54Z |
Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updates
|
YU-YUN SHAO; Lin H.-J. |
| 臺大學術典藏 |
2021-08-03T07:10:54Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; YU-YUN SHAO; Lee J.-M.; Hsu C.; Hsu C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Solving the deficit of cancer pain management skills by education programs
|
YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-03T07:10:52Z |
An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
|
YU-YUN SHAO; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-03T07:10:52Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-07-27T03:03:31Z |
Beta-Human Chorionic Gonadotropin Secreting Germinoma Refractory to Multi-Modality Treatment: A Case Report.
|
WEI-LI MA; Feng-Ming Hsu; Sung-Hsin Kuo; Yu-Yun Shao |
| 臺大學術典藏 |
2021-04-29T06:48:27Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Yu-Yun Shao; Shen-Yung Wang; Shi-Ming Lin; Diagnosis Group; Systemic Therapy Group; KAI-WEN HUANG |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Yu-Yun Shao;Hsu C.;Hsu C.-H.;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Yu-Yun Shao;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Hsu C.;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
Whsc1 promotes cell proliferation, migration, and invasion in hepatocellular carcinoma by activating mtorc1 signaling
|
Dai J.; Jiang L.; Qiu L.; YU-YUN SHAO; Shi P.; Li J. |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
Solving the deficit of cancer pain management skills by education programs
|
YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-02-25T07:00:57Z |
It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
|
Liu T.-H.; YU-YUN SHAO; Hsu C.-H. |
| 臺大學術典藏 |
2021-02-25T07:00:57Z |
Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma
|
Wu C.-H.; Liang P.-C.; Hsu C.-H.; Chang F.-T.; YU-YUN SHAO; Ting-Fang Shih T. |
| 臺大學術典藏 |
2021-02-25T07:00:57Z |
Hepatitis B virus infection and the risk of cancer among the Chinese population
|
Tian T.; Song C.; Jiang L.; Dai J.; Lin Y.; Xu X.; Yu C.; Ge Z.; Ding Y.; Wen Y.; Liu B.; YU-YUN SHAO; Shi P.; Zhu C.; Liu Y.; Jing S.; Wang Z.; Hu Z.; Li J. |
| 臺大學術典藏 |
2021-02-25T07:00:56Z |
Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma
|
Wu C.-H.; YU-YUN SHAO; Ting-Fang Shih T. |
| 臺大學術典藏 |
2021-01-18T09:11:58Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
YI-PING HUNG; YU-YUN SHAO; Chiun Hsu; CHIH-HUNG HSU; Lee, Jan Mou; Yang, Muh Hwa; Chao, Yee |
